Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
Shan LiJuan LiWenjing ShiZiyan NieShasha ZhangFengdie MaJun HuJianjun ChenPeiqiang LiXiao-Dong XiePublished in: Biomolecules (2023)
Around 11% of all known gene lesions causing human genetic diseases are nonsense mutations that introduce a premature stop codon (PTC) into the protein-coding gene sequence. Drug-induced PTC readthrough is a promising therapeutic strategy for treating hereditary diseases caused by nonsense mutations. To date, it has been found that more than 50 small-molecular compounds can promote PTC readthrough, known as translational readthrough-inducing drugs (TRIDs), and can be divided into two major categories: aminoglycosides and non-aminoglycosides. This review summarizes the pharmacodynamics and clinical application potential of the main TRIDs discovered so far, especially some newly discovered TRIDs in the past decade. The discovery of these TRIDs brings hope for treating nonsense mutations in various genetic diseases. Further research is still needed to deeply understand the mechanism of eukaryotic cell termination and drug-induced PTC readthrough so that patients can achieve the greatest benefit from the various TRID treatments.
Keyphrases
- drug induced
- liver injury
- genome wide
- copy number
- end stage renal disease
- endothelial cells
- ejection fraction
- newly diagnosed
- adverse drug
- chronic kidney disease
- amino acid
- stem cells
- prognostic factors
- risk assessment
- gene expression
- patient reported outcomes
- binding protein
- bone marrow
- induced pluripotent stem cells
- transcription factor